STING1 and cancer: For example, combination therapy of STING agonist and anti‐transforming growth factor β/PD‐L1 bispecific antibody YM101 produced robust innate and adaptive antitumor responses in immunotherapy‐resistant cancer models by recruiting immune cells and stimulating their function.418